QRD statements for metered dose inhalers containing fluorinated greenhouse gases

2024 European Medicines Agency annual report on independence

Applying for marketing authorisation: orphan medicines

Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva, efavirenz,emtricitabine,tenofovir disoproxil, Date of authorisation: 17/07/2017, Revision: 12, Status: Authorised

Clinical Trial Information System (CTIS) structured data form - Initial application, additional Member State Concerned, substantial modification, non-substantial modification

Opinion on medicine for use outside EU: Ivermectin/Albendazole, ivermectin,albendazole, Parasitic Diseases,Helminthiasis,Hookworm Infections,Ascaridida Infections,Trichuriasis,Strongyloidiasis, 30/01/2025 Positive opinion

Human medicines European public assessment report (EPAR): Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.), beclometasone,formoterol, Date of authorisation: 23/04/2018, Revision: 7, Status: Withdrawn

Opinion/decision on a Paediatric investigation plan (PIP): Rapiscan, Regadenoson, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Surgical and medical procedures, PIP number: P/0029/2024

Agenda of the CAT meeting 19-21 March 2025

ICH M11 Technical Specification - Updated step 2b